Lumen Bioscience reels in $16M Series B to 'democratize' biologics
It all started with spirulina — a nutrient-packed superfood popular on the West Coast.
The photosynthetic microalgae has been commercially farmed since the 1970s. But Lumen Bioscience co-founders Brian Finrow and Jim Roberts aren’t looking to supplement their diets. They believe spirulina can be engineered to deliver therapeutic proteins and treat diseases like traveler’s diarrhea, norovirus and C. difficile colitis. And Lumen just reeled in a $16 million Series B to prove it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.